Abstract:The identification of protective agents for the treatment of neurodegenerative diseases is the mainstay therapeutic goal to modify the disease course and arrest the irreversible disability progression. Pharmacological therapies synergistically targeting multiple pathogenic pathways, including oxidative stress, mitochondrial dysfunction, and inflammation, are prime candidates for neuroprotection. Combination or synergistic therapy with melatonin, whose decline correlates with altered sleep/wake cycle and impaired glymphatic "waste clearance" system in neurodegenerative diseases, has a great therapeutic potential to treat inflammatory neurodegenerative states. Despite the protective outcomes observed in preclinical studies, mild or poor outcomes were observed in clinical settings, suggesting that melatonin combinations promoting synergistic actions at appropriate doses might be more suitable to treat multifactorial neurodegenerative disorders. In this review, we first summarize the key melatonin actions and pathways contributing to cell protection and its therapeutic implication in Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). We remark the major controversies in the field, mostly generated by the lack of a common consensus for the optimal dosing, molecular targets, and toxicity. Then, we review the literature investigating the efficacy of melatonin combinations with approved or investigational neuroprotective agents and of melatonin‐containing hybrid molecules, both in vitro and in animal models of AD, PD, and MS, as well as the efficacy of add‐on melatonin in clinical settings. We highlight the rationale for such melatonin combinations with a focus on the comparison with single‐agent treatment and on the assays in which an additive or a synergistic effect has been achieved. We conclude that a better characterization of the mechanisms underlying such melatonin synergistic actions under neuroinflammation at appropriate doses needs to be tackled to advance successful clinical translation of neuroprotective melatonin combination therapies or melatonin‐based hybrid molecules.

Melatonin and Autophagy in Aging-Related Neurodegenerative Diseases

Exploring the multifunctional role of melatonin in regulating autophagy and sleep to mitigate Alzheimer's disease neuropathology

Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes

Autophagy in Aging and Neurodegenerative Diseases: Implications for Pathogenesis and Therapy.

Melatonin regulates A production/clearance balance and A neurotoxicity: A potential therapeutic molecule for Alzheimer's disease

The Therapeutic Potential of Melatonin in Alzheimer's Disease: A Comprehensive Review

The Vital Role of Melatonin and Its Metabolites in the Neuroprotection and Retardation of Brain Aging

Modulation of autophagy by melatonin and its receptors: implications in brain disorders

Dysfunctional mitochondria in age-related neurodegeneration: Utility of melatonin as an antioxidant treatment

Alzheimer's disease: pathological mechanisms and the beneficial role of melatonin

Role of melatonin in regulating neurogenesis: Implications for the neurodegenerative pathology and analogous therapeutics for Alzheimer’s disease

Melatonin: A potential nighttime guardian against Alzheimer's

Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases

The Protective Effects of Melatonin on Neural Degenerative Disease and Postoperative Cognitive Dysfunction

Autophagy, aging, and age-related neurodegeneration

Autophagy in Alzheimer's Disease Pathogenesis: Therapeutic Potential and Future Perspectives.

Melatonin Supplementation, a Strategy to Prevent Neurological Diseases Through Maintaining Integrity of Blood Brain Barrier in Old People.

Melatonin Ameliorates Cognitive Deficits Through Improving Mitophagy in a Mouse Model of Alzheimer's Disease

Melatonin-mediated calcineurin inactivation attenuates amyloid beta-induced apoptosis

Autophagy Modulation for Alzheimer's Disease Therapy.

Protective Activity of Melatonin Combinations and Melatonin‐Based Hybrid Molecules in Neurodegenerative Diseases